Lensar, Inc. LNSR
We take great care to ensure that the data presented and summarized in this overview for LENSAR, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LNSR
View all-
North Run Capital, LP Wellesley, MA1.1MShares$8.27 Million7.54% of portfolio
-
Park West Asset Management LLC Larkspur, CA990KShares$7.46 Million0.37% of portfolio
-
Dimensional Fund Advisors LP Austin, TX649KShares$4.89 Million0.0% of portfolio
-
Brandes Investment Partners, LP La Jolla, CA443KShares$3.34 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA433KShares$3.27 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny308KShares$2.32 Million0.0% of portfolio
-
Dcf Advisers, LLC Greenwich, CT241KShares$1.81 Million0.46% of portfolio
-
Clearline Capital LP New York, NY173KShares$1.3 Million0.03% of portfolio
-
Black Rock Inc. New York, NY154KShares$1.16 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA100KShares$757,2490.0% of portfolio
Latest Institutional Activity in LNSR
Top Purchases
Top Sells
About LNSR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Insider Transactions at LNSR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 03
2024
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
685
+0.84%
|
$2,740
$4.5 P/Share
|
|
Aug 28
2024
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
1,000
+1.23%
|
$4,000
$4.45 P/Share
|
|
Aug 27
2024
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
500
+0.63%
|
$2,000
$4.5 P/Share
|
|
Aug 26
2024
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
802
+1.01%
|
$3,208
$4.58 P/Share
|
|
Aug 22
2024
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
2
+0.0%
|
$8
$4.3 P/Share
|
|
Aug 21
2024
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
500
+0.64%
|
$2,000
$4.35 P/Share
|
|
Aug 20
2024
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
500
+0.64%
|
$2,000
$4.2 P/Share
|
|
Aug 16
2024
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
6
+0.01%
|
$24
$4.03 P/Share
|
|
Aug 14
2024
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
1,000
+1.28%
|
$4,000
$4.2 P/Share
|
|
Aug 12
2024
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
500
+0.65%
|
$2,000
$4.03 P/Share
|
|
Aug 08
2024
|
Thomas R Staab Ii Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+2.11%
|
$7,000
$2.65 P/Share
|
|
May 07
2024
|
Aimee S Weisner |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+20.45%
|
-
|
|
May 07
2024
|
William J Phd Link |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+3.89%
|
-
|
|
May 07
2024
|
Thomas B Ellis |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+41.29%
|
-
|
|
May 07
2024
|
Todd B Hammer |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+41.29%
|
-
|
|
May 07
2024
|
Richard L Md Lindstrom |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+8.43%
|
-
|
|
May 07
2024
|
Elizabeth G. O'Farrell |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+34.07%
|
-
|
|
May 07
2024
|
Gary M Winer |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+22.6%
|
-
|
|
May 06
2024
|
Nicholas T Curtis Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,400
+7.63%
|
-
|
|
May 06
2024
|
Thomas R Staab Ii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,000
+10.68%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 304K shares |
|---|---|
| Open market or private purchase | 5.5K shares |
| Exercise of conversion of derivative security | 3.5K shares |
| Payment of exercise price or tax liability | 4.12K shares |
|---|